Molecular Engineering of Quinolinium Cyanine Nanoagonist for Metastasis‐Suppressed NIR‐II Photothermal Immunotherapy

: 2.3-fold); (2) Immunophenotype reprogramming via pro-inflammatory M1 macrophage skewing (M1/M2: 2.55 vs. 0.33); (3) Metastatic suppression (96% reduced distal tumor burden). This thermo-immunological nanoplatform establishes crosstalk between localized hyperthermia and antitumor immunity, advancing a translatable paradigm for TNBC management.